Retail data analytics platform SYCARDA and Singapore-headquartered digital solutions provider CUE signed an MoU on February 2 to begin an era of innovative collaboration to produce more comprehensive and effective retail solutions across Malaysia, Singapore, and eventually the rest of Asia.

Both organisations have consistently prioritised their dedication to adding value to clients’ systems and ways of working towards more dynamic retail data solutions, knowledge exchange in data analytics, visual AI, and machine learning. Upon officiating this collaboration, SYCARDA and CUE will integrate their expertise and develop a bespoke retail solution to address a Malaysian grocery chain’s pilferage and sweethearting issue.

SYCARDA’s mission is to assist traditional brick-and-mortar retailers to reduce their costs and increase their revenue in a rapidly challenging retail landscape by using data analytics and business intelligence. The platform is completely independent and can be used across most Points-of-Sale (POS) without the need for integration, which enabled SYCARDA to be deployed across 2,000 retail and food and beverage outlets across Southeast Asia.

Similarly, CUE Group’s customised and flexible commerce solutions and range of practice in various industries speak to its understanding of the value of research and development. From standardising security systems to improving the customer journey with visual AI, CUE Group’s solutions result in-depth consumer tracking and seamless transactions, spelling the difference for businesses across the food and beverage, automotive, FMCG, and pharmaceutical industries. Products such as RetailX enable retailers to improve and tailor their in-store experiences to better serve their customers, as well as to develop an accurate target audience profile that will boost precision marketing strategies.

With the rest of 2023 predicted to be a time of slow economic recovery in Asia, there is some room for market confidence with declining inflation rates. Still, with many businesses suffering an average pilferage rate of 5%, solutions more intelligent and enterprising than supply chain vigilance are required. By combining CUE’s computer vision analytics and SYCARDA’s POS data points, this partnership enables businesses to obtain more accurate and actionable insights into their business operations and customer experience.

“We see that the SME retail sector tends to go disappointingly under-served, with many of its problems unaddressed,” said Vernon Chua, CEO of SYCARDA. “What we’re hoping to create together [with CUE] is a way to see these problems and solve them pretty much as they happen – more than saving money, it’s about making businesses the best they can be and at an affordable rate that allows them to multiply their ROI.”

“We see a fellow enabler in SYCARDA and we’re optimistic about where this partnership can take the Southeast Asian market,” said Zainudin Nordin, Executive Director of CUE Group, SEA. “Neither of us is a big proponent of development for development’s sake; just as our services and solutions [at CUE] are ‘smart’ in the technological sense, we strive to also fulfill that in the business sense.”

<h1>SYCARDA, CUE Group Join Forces To Revolutionize Retail Solutions in ASEAN</h1>SYCARDA, a Malaysian leading retail data analytics platform, has joined forces with Singapore's digital solutions giant, CUE Group. On this year, the two companies solidified their partnership by signing a Memorandum of Understanding. This collaboration is set to revolutionize retail solutions, starting in Malaysia and Singapore, with plans to expand across Asia. The primary motivation behind this alliance is to address prevalent challenges in the retail sector, notably pilferage and sweethearting issues faced by a Malaysian grocery chain. By synergizing CUE's advanced computer vision analytics with SYCARDA's cutting-edge retail data analytics solution, they aim to equip businesses with profound and actionable insights, enhancing both operations and customer experience.Retail data analytics platform SYCARDA and Singapore-headquartered digital solutions provider CUE signed an MoU on February 2 to begin an era of innovative collaboration to produce more comprehensive and effective retail solutions across Malaysia, Singapore, and eventually the rest of Asia.Both organisations have consistently prioritised their dedication to adding value to clients’ systems and ways of working towards more dynamic retail data solutions, knowledge exchange in data analytics, visual AI, and machine learning. Upon officiating this collaboration, SYCARDA and CUE will integrate their expertise and develop a bespoke retail solution to address a Malaysian grocery chain’s pilferage and sweethearting issue.SYCARDA’s mission is to assist traditional brick-and-mortar retailers to reduce their costs and increase their revenue in a rapidly challenging retail landscape by using data analytics and business intelligence. The platform is completely independent and can be used across most Points-of-Sale (POS) without the need for integration, which enabled SYCARDA to be deployed across 2,000 retail and food and beverage outlets across Southeast Asia.Similarly, CUE Group’s customised and flexible commerce solutions and range of practice in various industries speak to its understanding of the value of research and development. From standardising security systems to improving the customer journey with visual AI, CUE Group’s solutions result in-depth consumer tracking and seamless transactions, spelling the difference for businesses across the food and beverage, automotive, FMCG, and pharmaceutical industries. Products such as RetailX enable retailers to improve and tailor their in-store experiences to better serve their customers, as well as to develop an accurate target audience profile that will boost precision marketing strategies.With the rest of 2023 predicted to be a time of slow economic recovery in Asia, there is some room for market confidence with declining inflation rates. Still, with many businesses suffering an average pilferage rate of 5%, solutions more intelligent and enterprising than supply chain vigilance are required. By combining CUE’s computer vision analytics and SYCARDA’s POS data points, this partnership enables businesses to obtain more accurate and actionable insights into their business operations and customer experience.“We see that the SME retail sector tends to go disappointingly under-served, with many of its problems unaddressed,” said Vernon Chua, CEO of SYCARDA. “What we’re hoping to create together [with CUE] is a way to see these problems and solve them pretty much as they happen – more than saving money, it’s about making businesses the best they can be and at an affordable rate that allows them to multiply their ROI.”“We see a fellow enabler in SYCARDA and we’re optimistic about where this partnership can take the Southeast Asian market,” said Zainudin Nordin, Executive Director of CUE Group, SEA. “Neither of us is a big proponent of development for development’s sake; just as our services and solutions [at CUE] are ‘smart’ in the technological sense, we strive to also fulfill that in the business sense.”SYCARDA is a leading retail data analytics platform designed to empower brick-and-mortar retailers in navigating the modern retail environment. The platform's strength lies in its adaptability, allowing seamless deployment across over 2,000 retail and food and beverage outlets in Southeast Asia without the need for intricate integrations. With a focus on reducing operational costs and boosting revenue, SYCARDA offers retailers real-time, actionable insights to stay agile and ahead of market trends. Committed to innovation, SYCARDA ensures that businesses, regardless of size, have the tools and insights necessary to thrive in today's challenging retail landscape.See Lik Weng (Bob)
+60123315099
bob@sycarda.ai

Department stores / Supermarkets / Convenience stores / Stores

Restaurant / Fast food / Streetfood

Pharmaceuticals

International activity

SMEs

SYCARDA, a Malaysian leading retail data analytics platform, has joined forces with Singapore's digital solutions giant, CUE Group. On this year, the two companies solidified their partnership by signing a Memorandum of Understanding. This collaboration is set to revolutionize retail solutions, starting in Malaysia and Singapore, with plans to expand across Asia. The primary motivation behind this alliance is to address prevalent challenges in the retail sector, notably pilferage and sweethearting issues faced by a Malaysian grocery chain. By synergizing CUE's advanced computer vision analytics with SYCARDA's cutting-edge retail data analytics solution, they aim to equip businesses with profound and actionable insights, enhancing both operations and customer experience.

SYCARDA, CUE Group Join Forces To Revolutionize Retail Solutions in ASEAN

Practice Note 17 (PN17) company, Pharmaniaga Bhd, is planning to undertake a private placement of up to 131.02 million new shares, representing 10% of its total issued shares, to raise approximately RM44.55 million in funds for working capital.

It told the bourse in filing today that the issue price of the shares will be determined at a later stage.

As of June 12 2023, Pharmaniaga’s issued share capital stands at RM154.18 million comprising 1.31 million shares. Therefore, the proposed private placement involves the issuance of up to 131 million new shares, which accounts for 10% of the total issued shares.

The indicative issue price for the placement shares is 34 sen per share, representing a discount of 3.72 sen or 9.86% to the 5-day volume-weighted average market price (VWAMP) of Pharmaniaga shares as of the latest practicable date.

The placement shares will be offered to third-party investors who qualify under the Capital Markets and Services Act, 2007.

The proceeds from the private placement, estimated at RM44.55 million, will be utilised for working capital and expenses related to the proposal.

Pharmaniaga aims to allocate RM44.21 million for working capital within 12 months and RM336,000 for estimated expenses within one month of receiving the placement funds.

The company’s trade payables as of March 31, 2023, amounted to approximately RM722.3 million, while its cash and bank balances stood at approximately RM56.6 million.

The decision to pursue a private placement stems from Pharmaniaga’s classification as a PN17 company.

On Feb 27 2023, the company triggered the prescribed criteria of PN17 of the Malaysian Main Market Listing Requirements (MMLR). Subsequently, on May 2 2023, Pharmaniaga triggered an additional prescribed criteria under PN17.

Pharmaniaga said the private placement will enable the company to raise funds while formulating a plan to regularise its financial condition, which must be submitted to Bursa Securities within 12 months from February 27, 2023.

After considering various fundraising methods, such as rights issue and bank borrowings, Pharmaniaga believes that the proposed private placement is the most suitable option at this time.&nbsp;

It said the exercise offers an expeditious and cost-effective way of raising capital from the market, compared to a pro-rata issuance like a rights issue.

Additionally, the private placement allows the company to raise funds without incurring interest costs associated with bank borrowings or debt instrument issuance.

It added that this approach helps preserve the company’s cash flow for reinvestment and operational needs, while also strengthening its capital base and financial position.

Although the private placement may result in dilution for existing shareholders, Pharmaniaga expects the raised funds to contribute positively to its future earnings.

Looking ahead, Pharmaniaga remains optimistic about its prospects and future plans.

The company said it is actively working on a strategic plan to recover from the PN17 classification and formulate regularisation plans with its appointed advisors.

It anticipates concluding negotiations with the Ministry of Health (MOH) for concession renewal by the end of June 2023, which would further strengthen its presence in the public sector.

Pharmaniaga is also focused on expanding its capabilities in the field of biopharmaceuticals.

It is establishing manufacturing facilities for vaccines and insulin to address the increasing demand in these therapeutic areas, primarily targeting vaccines under the National Immunisation Programme.

The company aims to commercialise vaccines by 2025 and insulin by 2026.&nbsp;

This strategic move aligns with the company’s commitment to meeting the healthcare needs of the population and ensuring the timely delivery of essential drugs and non-drug products to government facilities across the country.

To facilitate technology transfer and enhance its global reach, Pharmaniaga plans to collaborate with strategic partners from Europe, India, South Korea, and China.&nbsp;

These partnerships will enable the company to leverage their expertise and expand its biopharmaceutical capabilities further.

In addition to biopharmaceuticals, Pharmaniaga intends to intensify its research and development (R&amp;D) activities to develop new high-value pharmaceutical products.&nbsp;

With 101 new products in its five year product development pipeline, the company aims to introduce a range of offerings in therapeutic areas such as cardiovascular systems, anti-diabetic treatments, and supplements.

By focusing on off-patent originator products, Pharmaniaga aims to become a market leader, gaining early market share and expanding its product portfolio.

Pharmaniaga said its sales and marketing team will play a pivotal role in promoting its extensive array of healthcare products across medical and non-medical channels.

With a significant market share in Malaysia’s private generic market, the company is well-positioned for further growth.

The anticipated growth in the local private market, driven by the introduction of new drug launches and the success of existing market-leading brands, presents promising opportunities for Pharmaniaga to expand its market presence and increase its revenue.

Moreover, Pharmaniaga is actively pursuing expansion in Indonesia.

Through its subsidiary PT Millennium Pharmacon International (MPI), the company is establishing new branches to strengthen its logistics and distribution capabilities in the country.

With a central warehouse in Jakarta and 33 branches throughout Indonesia, Pharmaniaga’s operations are steadily gaining ground in both the pharmaceutical and over-the-counter product markets.

Pharmaniaga shares slid 1 sen or 2.56% to close at 38 sen today, while its market capitalisation stood at RM498 million.

<h1>Pharmaniaga plans private placement to raise RM44.5m for recovery and expansion</h1>Practice Note 17 (PN17) company, Pharmaniaga Bhd, is planning to undertake a private placement of up to 131.02 million new shares, representing 10% of its total issued shares, to raise approximately RM44.55 million in funds for working capital.It told the bourse in filing today that the issue price of the shares will be determined at a later stage.As of June 12 2023, Pharmaniaga’s issued share capital stands at RM154.18 million comprising 1.31 million shares. Therefore, the proposed private placement involves the issuance of up to 131 million new shares, which accounts for 10% of the total issued shares.The indicative issue price for the placement shares is 34 sen per share, representing a discount of 3.72 sen or 9.86% to the 5-day volume-weighted average market price (VWAMP) of Pharmaniaga shares as of the latest practicable date.The placement shares will be offered to third-party investors who qualify under the Capital Markets and Services Act, 2007.The proceeds from the private placement, estimated at RM44.55 million, will be utilised for working capital and expenses related to the proposal.Pharmaniaga aims to allocate RM44.21 million for working capital within 12 months and RM336,000 for estimated expenses within one month of receiving the placement funds.The company’s trade payables as of March 31, 2023, amounted to approximately RM722.3 million, while its cash and bank balances stood at approximately RM56.6 million.The decision to pursue a private placement stems from Pharmaniaga’s classification as a PN17 company.On Feb 27 2023, the company triggered the prescribed criteria of PN17 of the Malaysian Main Market Listing Requirements (MMLR). Subsequently, on May 2 2023, Pharmaniaga triggered an additional prescribed criteria under PN17.Pharmaniaga said the private placement will enable the company to raise funds while formulating a plan to regularise its financial condition, which must be submitted to Bursa Securities within 12 months from February 27, 2023.After considering various fundraising methods, such as rights issue and bank borrowings, Pharmaniaga believes that the proposed private placement is the most suitable option at this time.&nbsp;It said the exercise offers an expeditious and cost-effective way of raising capital from the market, compared to a pro-rata issuance like a rights issue.Additionally, the private placement allows the company to raise funds without incurring interest costs associated with bank borrowings or debt instrument issuance.It added that this approach helps preserve the company’s cash flow for reinvestment and operational needs, while also strengthening its capital base and financial position.Although the private placement may result in dilution for existing shareholders, Pharmaniaga expects the raised funds to contribute positively to its future earnings.Looking ahead, Pharmaniaga remains optimistic about its prospects and future plans.The company said it is actively working on a strategic plan to recover from the PN17 classification and formulate regularisation plans with its appointed advisors.It anticipates concluding negotiations with the Ministry of Health (MOH) for concession renewal by the end of June 2023, which would further strengthen its presence in the public sector.Pharmaniaga is also focused on expanding its capabilities in the field of biopharmaceuticals.It is establishing manufacturing facilities for vaccines and insulin to address the increasing demand in these therapeutic areas, primarily targeting vaccines under the National Immunisation Programme.The company aims to commercialise vaccines by 2025 and insulin by 2026.&nbsp;This strategic move aligns with the company’s commitment to meeting the healthcare needs of the population and ensuring the timely delivery of essential drugs and non-drug products to government facilities across the country.To facilitate technology transfer and enhance its global reach, Pharmaniaga plans to collaborate with strategic partners from Europe, India, South Korea, and China.&nbsp;These partnerships will enable the company to leverage their expertise and expand its biopharmaceutical capabilities further.In addition to biopharmaceuticals, Pharmaniaga intends to intensify its research and development (R&amp;D) activities to develop new high-value pharmaceutical products.&nbsp;With 101 new products in its five year product development pipeline, the company aims to introduce a range of offerings in therapeutic areas such as cardiovascular systems, anti-diabetic treatments, and supplements.By focusing on off-patent originator products, Pharmaniaga aims to become a market leader, gaining early market share and expanding its product portfolio.Pharmaniaga said its sales and marketing team will play a pivotal role in promoting its extensive array of healthcare products across medical and non-medical channels.With a significant market share in Malaysia’s private generic market, the company is well-positioned for further growth.The anticipated growth in the local private market, driven by the introduction of new drug launches and the success of existing market-leading brands, presents promising opportunities for Pharmaniaga to expand its market presence and increase its revenue.Moreover, Pharmaniaga is actively pursuing expansion in Indonesia.Through its subsidiary PT Millennium Pharmacon International (MPI), the company is establishing new branches to strengthen its logistics and distribution capabilities in the country.With a central warehouse in Jakarta and 33 branches throughout Indonesia, Pharmaniaga’s operations are steadily gaining ground in both the pharmaceutical and over-the-counter product markets.Pharmaniaga shares slid 1 sen or 2.56% to close at 38 sen today, while its market capitalisation stood at RM498 million.Established in 1994, Pharmaniaga has evolved to become one of Malaysia’s largest listed integrated pharmaceutical groups. Our participation in the sector spans across the pharmaceutical value chain from research and development to the production of generic drugs, over-the-counter medicines, logistics and distribution, sales and marketing. In 2021, we made history by becoming the first Malaysian pharmaceutical company to fill and finish manufacture a human vaccine.

Already a formidable player in the domestic market, we continue to explore the strategic expansion of our international reach.No. 7, Lorong Keluli 1B,
Kawasan Perindustrian Bukit Raja Selatan,
Seksyen 7, 40000 Shah Alam,
Selangor Darul Ehsan

Tel : +603-3342 9999
Fax : +603-3341 7777

info@pharmaniaga.com

Diet / Health food / Supplement

Fitness / Healthcare

Medical / Hospital

Financial results announcement

Pharmaniaga plans private placement to raise RM44.5m for recovery and expansion

ALPS had announced last month the underwriting exercise for CILO’s Special Purpose Acquisition Company (SPAC) for listing in Johannesburg Stock Exchange. 

With this underwriting exercise, ALPS will be able to develop more drugs for medical purpose to serve the humanity. The company positions itself as a disruptive international health solutions company that focuses on an individual’s wellness, performance, and longevity goals. 

ALPS’ Founder and Group CEO, Dr Tham Seng Kong had visited the CILO’s plant (pharmaceutical) at Johannesburg, South Africa in December 2022. This pharmaceutical company was GACP and GMP certified since year 2020, making CCP the first company in South Africa to have both GACP and GMP cannabis licenses in one company. 

On the other hand, ALPS business focus is on the perception that the use of precision &amp; preventive medicine as therapeutic entities will drive one of the next most important phases in medicine and wellness. ALPS has the leading edge technology &amp; the necessary expertise (scientists, technological resources, researchers &amp; equipment) all in place, all cutting edge, advancing with momentum. ALPS is currently one of the most progressive Biomarker Precision Diagnostic Lab with full instrument WGS Provider and cGMP stem cell cultivation in the ASEAN region, with a business focus on molecular cells as therapeutic entities. 

ALPS trusts the collaboration with CILO will lay a firmer foundation between both parties, not only on developing more drugs for future medical purpose to serve the humanity, but also on ushering CILO closer towards the IPO in Johannesburg Stock Exchange (JSE).

<h1>ALPS GLOBAL HOLDING BERHAD partnering with CILO CYBIN to list Africa’s first Cannabis on Main Board of Johannesburg Stock Exchange (JSE)</h1>ALPS had announced last month the underwriting exercise for CILO’s Special Purpose Acquisition Company (SPAC) for listing in Johannesburg Stock Exchange.<img style="max-width:100%;height:auto;" src="https://vritimes-public.s3.ap-southeast-1.amazonaws.com/production/721a2bfa883ac3cd97397699f32a47db4ace3ab68f82e887eee584dfb8c1a156/WhatsApp%20Image%202023-05-23%20at%2011.37.26.jpeg" alt="22/5/2023 Courtesy visit by Mr. Gabriel Theron, Founder and CEO of CILO CYBIN HOLDINGS LTD."/>ALPS had announced last month the underwriting exercise for CILO’s Special Purpose Acquisition Company (SPAC) for listing in Johannesburg Stock Exchange. With this underwriting exercise, ALPS will be able to develop more drugs for medical purpose to serve the humanity. The company positions itself as a disruptive international health solutions company that focuses on an individual’s wellness, performance, and longevity goals. ALPS’ Founder and Group CEO, Dr Tham Seng Kong had visited the CILO’s plant (pharmaceutical) at Johannesburg, South Africa in December 2022. This pharmaceutical company was GACP and GMP certified since year 2020, making CCP the first company in South Africa to have both GACP and GMP cannabis licenses in one company. On the other hand, ALPS business focus is on the perception that the use of precision &amp; preventive medicine as therapeutic entities will drive one of the next most important phases in medicine and wellness. ALPS has the leading edge technology &amp; the necessary expertise (scientists, technological resources, researchers &amp; equipment) all in place, all cutting edge, advancing with momentum. ALPS is currently one of the most progressive Biomarker Precision Diagnostic Lab with full instrument WGS Provider and cGMP stem cell cultivation in the ASEAN region, with a business focus on molecular cells as therapeutic entities. ALPS trusts the collaboration with CILO will lay a firmer foundation between both parties, not only on developing more drugs for future medical purpose to serve the humanity, but also on ushering CILO closer towards the IPO in Johannesburg Stock Exchange (JSE).ALPS GLOBAL HOLDING BERHAD
(Incorporated in Malaysia)
(Registration No : 1227032-V)
For further information, you may contact :
FIONA HON
Telephone : +603 2163 1113
Email : fiona@alpsmedical.com

Health and Beauty appliances

STEM (Science, Tech, Engineering, Math)

Listed companies

ALPS had announced last month the underwriting exercise for CILO’s Special Purpose Acquisition Company (SPAC) for listing in Johannesburg Stock Exchange.